3092-LB: Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysis

Introduction and Objective: The beneficial effects of obesity management medications (OMMs) on weight loss are well recognized, but their impact on physical function remains incompletely understood. This systematic review and meta-analysis evaluated the effect of OMMs on physical function. Methods: Eligible studies included randomized controlled trials of adults with overweight or obesity treated with an FDA-approved OMM (i.e., orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, setmelanotide, semaglutide, tirzepatide). PubMed, Embase, and CINAHL databases were searched from inception through August 2025. Physical function outcomes included validated self-report or objective measures. Risk of bias was evaluated using the Cochrane Risk-of-Bias tool (version 2). Random-effects meta-analyses were conducted to estimate pooled mean differences (MD). Inter-study heterogeneity was assessed using the I2 statistic and Cochran’s Q test. Results: Thirty studies with 25,068 participants were included. Relative to control, self-reported physical function improved with OMMs on both the Short-Form-36 (MD: 1.76 [95% CI: 1.20 to 2.32], I2 = 62.5%, p < 0.01) and Impact of Weight on Quality-of-Life (MD: 5.58, [95% CI: 4.24 to 6.92], I2 = 65.8%, p < 0.01) self-report measures. Three studies reported objective physical function, suggesting modest gains relative to control (Six-Minute Walk Test MD: 13.95, [95% CI: 5.84 to 22.07], I2 = 31.8%, p = 0.23). Conclusion: OMMs improved patients’ perceived physical function. Current evidence is largely based on self-reported outcomes, and incorporating objective functional assessments into research is needed to further evaluate treatment effectiveness. Disclosure A. Peary: None. F. Montoya: None. N. Vaidya: None. M. Li: None. S.N. Lopez: None. C. Santos: None. J. Tong: None. A.M. Chao: Advisory Panel; Current; Eli Lilly and Company. Advisory Panel; Ended; Novo Nordisk. Advisory Panel; Current; Boehringer Ingelheim International GmbH. Advisory Panel; Ended; Roche Pharmaceuticals. Research Support; Current; Eli Lilly and Company.